The vagus nerve stimulation device market has expanded rapidly, and the range of available devices now spans from FDA-cleared medical devices costing thousands of pounds to consumer wellness products under a hundred. The devices differ in critical ways — stimulation targets, clinical evidence, regulatory status, and intended use — and understanding these differences is essential for choosing the right option. This review covers the main categories and specific devices, with emphasis on what the evidence actually supports for each.
FDA-Cleared Medical VNS Devices
Implantable VNS: LivaNova VNS Therapy
The LivaNova (formerly Cyberonics) VNS Therapy System is the original vagus nerve stimulator, FDA-approved for drug-resistant epilepsy since 1997 and treatment-resistant depression since 2005. It consists of a pulse generator implanted in the left chest wall with a lead electrode wrapped around the left cervical vagus nerve. A surgeon implants it under general anaesthesia, and stimulation parameters are programmed by a clinician.
The evidence base is extensive: decades of clinical data across thousands of patients. For epilepsy, approximately 50 percent of patients achieve at least a 50 percent reduction in seizure frequency after 2-3 years of stimulation, with benefits that typically improve over time. For depression, response rates of 30-40 percent have been reported in patients who had not responded to multiple antidepressants.
The device costs $20,000-$40,000 including implantation surgery, is available only through a prescribing neurologist or psychiatrist, and is covered by insurance for approved indications. It is not a consumer device and is appropriate only for patients with severe, treatment-resistant conditions who have been evaluated by a specialist.
gammaCore: Non-Invasive Cervical VNS
gammaCore (electroCore) is an FDA-cleared, prescription non-invasive vagus nerve stimulation (nVNS) device that delivers electrical stimulation through the skin of the neck over the cervical vagus nerve. It is cleared for acute treatment and prevention of migraine, cluster headache, and as adjunctive therapy for medication-overuse headache.
The device delivers a proprietary low-voltage electrical signal through two stainless steel contact surfaces pressed against the neck. Each stimulation takes 2 minutes and can be self-administered. The evidence base includes multiple randomised controlled trials: the ACT1 study showed gammaCore was superior to sham for acute cluster headache (response rate 34 percent vs 10 percent for sham at 15 minutes), and the PRESTO study demonstrated efficacy for acute migraine (30 percent pain-free at 30 minutes vs 17 percent for sham).
gammaCore requires a prescription and works on a usage-based model — each device is activated for a set number of stimulations, and patients obtain replacement units through their prescriber. Cost is approximately $500-$600 per month without insurance, though many insurance plans now cover it for approved indications. It is the strongest-evidenced non-invasive VNS device available.
Consumer Transcutaneous Auricular VNS (taVNS) Devices
These devices stimulate the auricular branch of the vagus nerve (ABVN) through the ear — specifically the tragus or cymba conchae, where vagal afferent fibres reach the skin surface. They do not require a prescription in most jurisdictions because they are marketed as wellness or general health devices rather than making specific medical claims.
Nurosym (formerly Parasym)
Nurosym is a taVNS device developed by Parasym Health that delivers biphasic electrical stimulation through an ear clip electrode targeting the tragus. It has been the subject of multiple published clinical studies, including a randomised controlled trial showing improvements in heart rate variability in patients with heart failure (Stavrakis et al., JACC, 2020) and studies in atrial fibrillation and inflammatory conditions.
The device uses a 25 Hz stimulation frequency with adjustable intensity, controlled through a smartphone app. Sessions are typically 30-60 minutes. The evidence base for Nurosym is stronger than for most consumer taVNS devices because Parasym has invested in clinical research — an important differentiator in a market where many devices have no published evidence. Cost is approximately $500-$600.
Pulsetto
Pulsetto is a neck-worn taVNS device that delivers stimulation through the skin of the cervical region rather than through the ear. It targets the cervical vagus nerve area with electrical stimulation during short sessions (4-10 minutes). The company markets it primarily for stress reduction and sleep improvement.
The key consideration with Pulsetto and similar cervical consumer devices is that they are positioned differently from gammaCore (which is also cervical but FDA-cleared with RCT evidence). Pulsetto does not have FDA clearance for treating any specific medical condition and is marketed as a wellness device. The company has published some research, but the evidence base is thinner than that for Nurosym or gammaCore. Cost is approximately $250-$350.
Truvaga
Truvaga is a handheld cervical VNS device made by electroCore — the same company behind the prescription gammaCore. It uses similar technology but is marketed as an over-the-counter wellness device for stress management rather than a prescription medical device. It does not carry the same FDA clearances as gammaCore and is not indicated for migraine or cluster headache treatment.
The advantage of Truvaga is that it comes from a company with a strong clinical research track record (electroCore’s gammaCore has the most robust evidence base in non-invasive VNS). The limitation is that as a wellness-positioned device, it may use different stimulation parameters than the clinically validated gammaCore, and the clinical evidence supporting its specific configuration for its marketed uses (stress, wellness) is limited compared to gammaCore’s evidence for headache disorders. Cost is approximately $400-$500.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Clinician-applied tVNS
- Implanted VNS and neuromodulation
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
How to Evaluate Any VNS Device
The device market is crowded and the marketing often outpaces the evidence. When evaluating any VNS device, assess these factors.
Regulatory status. FDA clearance (or CE marking in Europe) for a specific condition means the device has been reviewed by regulators and has clinical data supporting efficacy and safety for that condition. “FDA registered” is different from “FDA cleared” — registration simply means the manufacturer has notified the FDA that they are selling the device, not that the FDA has reviewed its safety or efficacy. Many consumer taVNS devices are FDA-registered but not FDA-cleared.
Published clinical evidence. Look for randomised controlled trials (RCTs) with sham (placebo) control groups published in peer-reviewed journals. Open-label studies (where participants know they are receiving the active treatment) are susceptible to placebo effects, which are substantial for subjective outcomes like stress, anxiety, and pain. Case reports and testimonials are the weakest form of evidence.
Stimulation parameters. Effective VNS depends on frequency (typically 20-30 Hz for most applications), pulse width (200-500 microseconds), intensity (sufficient to activate vagal afferents without causing pain), and duty cycle (ratio of stimulation on-time to off-time). Devices that do not disclose their stimulation parameters or that use parameters far outside the ranges used in clinical research should be approached with caution.
Stimulation target. Cervical devices (targeting the neck) and auricular devices (targeting the ear) activate different portions of the vagus nerve and have different evidence bases. Cervical stimulation activates both afferent and efferent vagal fibres and has the strongest evidence for headache disorders. Auricular stimulation activates primarily afferent fibres and has growing evidence for cardiac, inflammatory, and neurological effects.
VNS Devices vs Self-Directed Vagal Techniques
Devices are not the only way to activate the vagus nerve. Slow diaphragmatic breathing at resonance frequency (approximately 6 breaths per minute), cold water face immersion (which triggers the dive reflex via vagal activation), humming and chanting (which activate vagal motor fibres to the larynx), and regular aerobic exercise all increase vagal tone as measured by HRV. These techniques are free, carry minimal risk, and have evidence from randomised controlled trials.
Devices offer a more controlled and reproducible stimulus than self-directed techniques, which matters for clinical applications where consistency is important. For general vagal tone improvement in healthy individuals, however, the evidence does not clearly show that devices produce superior outcomes compared to a consistent practice of breathing, exercise, and lifestyle interventions. Devices may be most valuable as a complement to self-directed techniques, or for individuals who find it difficult to maintain a consistent practice.
The right device is one component of a comprehensive vagal health strategy. My Vagus Nerve & Me covers the full range of approaches to strengthening your vagus nerve — from self-directed techniques to emerging technology. Get My Vagus Nerve & Me eBook and build an informed programme that works for you.
